Elacestrant in Preoperative Setting, a Window of Opportunity Study

Summary

ELIPSE is a window of opportunity, prospective, multicenter, phase 0 trial which evaluates the effect of Elacestrant on proliferation after 4 weeks of treatment in postmenopausal women with Estrogen Receptor-positive (ER+) and Human Epidermal Growth Factor Receptor 2-negative (HER2-negative) early breast cancer (BC) amenable to surgery.

Timeline

Start

2021-02-09

Primary completion

2022-02-08

Completion

2022-02-25

Drugs

Indications